← SynDRA
Frax486
SynDRA canonical compound SYN1608683 — structure-anchored drug synonym record
| Clinical phase | Preclinical |
|---|
| Primary target(s) | PAK1 | PAK2 | PAK3 | PAK4 |
|---|
| Mechanism of action | serine/threonine kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- PAK1 INHIBITOR
- PAK2 INHIBITOR
- PAK3 INHIBITOR
- PAK4 INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- PKN1
- SYK
- NTRK1
- NUAK1
- PAK5
- PAK6
- PDGFRA
- PDGFRB
- PDK1
- NEK6
- PHKG1
- PIK3C2B
- PIK3CA
- PIK3CG
- PIM1
- PIM2
- NLK
- ABL1
- PLK1
- NEK1
- MYLK2
- MTOR
- MST1R
- MST1
- MINK1
- MET
- MERTK
- MARK3
- MARK1
- MAPKAPK2
- MAPK9
- MAPK8
- NEK2
- PLK3
- MAPK14
- RPS6KA3
- YES1
- TYK2
- TSSK1B
- TGFBR1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- RefChem:921859
- FRAX 486
- C25H23Cl2FN6O
- GTPL8938
- orb1300418
- SCHEMBL10192789
- SCHEMBL29504158
- SCHEMBL31110556
- FRAX-486?
- GLXC-05228
- EX-A2201
- HZB03035
- BDBM50112355
- HY-15542B
- s7807
- AKOS024458531
- CCG-269796
- CS-3548
- SB17179
- NCGC00379255-04
- NCGC00379255-05
- NCGC00379255-06
- AC-33021
- DS-017730
- F6803
- T6840
- C71908
- F797085
- BRD-K57243773-001-01-6
- BRD-K57243773-001-02-4
Look up Frax486 in the interactive SynDRA portal →